NeuroSense Prices 750,000-Share PIPE at $0.80, Raising $600K with Insider Support
NeuroSense Therapeutics has agreed to sell 750,000 ordinary shares at $0.80 each in a private placement, raising $600,000 at a 6.7% premium to April 27 closing. CEO Alon Ben-Noon, CFO Or Eisenberg and a major shareholder each committed $200,000 with proceeds earmarked for general corporate purposes.
1. Private Placement Details
NeuroSense entered a definitive agreement to sell 750,000 ordinary shares at $0.80 per share in a private placement, raising gross proceeds of $600,000 at a price 6.7% above the prior closing price. The placement is subject to customary closing conditions and is expected to close during the week of May 3, 2026.
2. Insider and Shareholder Participation
CEO Alon Ben-Noon, CFO Or Eisenberg and a leading existing investor each committed $200,000 to the financing, demonstrating internal confidence in NeuroSense’s strategy and upcoming milestones.
3. Use of Proceeds and Company Focus
The company intends to use the proceeds for general corporate purposes ahead of key clinical and regulatory milestones for its neurodegenerative disease treatments, including programs targeting ALS, Alzheimer’s and Parkinson’s disease.